UK guidelines for referral and assessment of adults for heart transplantation

Heart

Volumn 97, Issue 18, 2011, Pages 1520-1527

  Banner, Nicholas R ^a,b,c   Bonser, Robert S ^d   Clark, Andrew L ^e   Clark, Stephen ^f   Cowburn, Peter J ^g   Gardner, Roy S ^h   Kalra, Paul R ⁱ   McDonagh, Theresa ^b,j   Rogers, Chris A ^c,k   Swan, Lorna ^j   Parameshwar, Jayan ^l   Thomas, Helen L ^m   Williams, Simon G ⁿ  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY OF HULL   (United Kingdom)

^f FREEMAN HOSPITAL   (United Kingdom)

^g SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^h GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

ⁱ QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BRISTOL   (United Kingdom)

^l PAPWORTH HOSPITAL   (United Kingdom)

^m NHS BLOOD AND TRANSPLANT   (United Kingdom)

ⁿ WYTHENSHAWE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGOXIN; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; IVABRADINE; LOOP DIURETIC AGENT; NICORANDIL; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT;

ADJUVANT THERAPY; ADULT; ANEMIA; CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGIST; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DISEASE COURSE; DIURESIS; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION DISSEMINATION; KIDNEY DISEASE; KIDNEY FUNCTION; LEFT VENTRICULAR ASSIST DEVICE; LIVER DYSFUNCTION; ORGAN DONOR; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT REFERRAL; PATIENT SELECTION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PULMONARY HYPERTENSION; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SODIUM INTAKE; THYROID DISEASE; TREATMENT CONTRAINDICATION; UNITED KINGDOM;

GREAT BRITAIN; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; PHYSICIAN'S ROLE; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; RISK FACTORS; WAITING LISTS;

EID: 80052170483     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300048     Document Type: Review

References (76)

1. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-94. (Pubitemid 46705572)
2. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
3. Stevenson LW, Miller LW, Desvigne-Nickens P, et al. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation 2004;110:975-81. (Pubitemid 39128623)
4. Banner NR, Rogers CA, Bonser RS. Effect of heart transplantation on survival in ambulatory and decompensated heart failure. Transplantation 2008;86:1515-22.
5. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report - 2009. J Heart Lung Transplant 2009;28:1007-22.
6. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda Conference: cardiac transplantation. Task Force 3: recipient guidelines/prioritization. J Am Coll Cardiol 1993;22:21-31.
7. Costanzo MR, Augustine S, Bourge R, et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995;92:3593-612.
8. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006;25:1024-42.
9. Transplant Activity in the UK, Report 2009/10. Bristol: NHS Blood and Transplant, 2010.
10. Thekkudan J, Rogers CA, Thomas HL, et al. Trends in adult heart transplantation: a national survey from the United Kingdom Cardiothoracic Transplant Audit 1995-2007. Eur J Cardiothorac Surg 2010;37:80-6.
11. Organs for Transplants: a report from the Organ Donation Task Force. UK: Department of Health, 2008.
12. Deng MC, De Meester JM, Smits JM, et al. Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group. BMJ 2000;321:540-5.
13. Almenar-Pertejo M, Almenar L, Martinez-Dolz L, et al. Study on health-related quality of life in patients with advanced heart failure before and after transplantation. Transplant Proc 2006;38:2524-6.
14. Kugler C, Tegtbur U, Gottlieb J, et al. Health-related quality of life in long-term survivors after heart and lung transplantation: a prospective cohort study. Transplantation 2010;90:451-7.
15. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
17. Bartoli E, Arras S, Faedda R, et al. Blunting of furosemide diuresis by aspirin in man. J Clin Pharmacol 1980;20:452-8.
18. de Silva R, Nikitin NP, Witte KK, et al. Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. Eur J Heart Fail 2007;9:415-23. (Pubitemid 46463937)
19. Anon. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
20. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
21. Costanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047-51.
22. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
23. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
24. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115:204-12. (Pubitemid 46105719)
25. Cowburn PJ, Patel H, Jolliffe RE, et al. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? Eur J Heart Fail 2005;7:215-17.
26. Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008;52:1239-46.
27. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
28. Gronda E, Bourge RC, Costanzo MR, et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006;25:1043-56.
29. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37. (Pubitemid 40110811)
30. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-8.
31. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. (Pubitemid 34984635)
32. Pfister R, Schneider CA. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides. Eur Heart J 2009;30:382-3.
33. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7.
34. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
35. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
36. O'Neill JO, Young JB, Pothier CE, et al. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta-blockers. Circulation 2005;111:2313-18.
37. Pfister R, Diedrichs H, Schiedermair A, et al. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail 2008;10:315-20.
38. Stevenson LW. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant 1991;10:468-76.
39. Rickenbacher PR, Trindade PT, Haywood GA, et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol 1996;27:1192-7.
40. Simmonds J, Burch M, Dawkins H, et al. Heart transplantation after congenital heart surgery: improving results and future goals. Eur J Cardiothorac Surg 2008;34:313-17.
41. Irving C, Parry G, O'Sullivan J, et al. Cardiac transplantation in adults with congenital heart disease. Heart 2010;96:1217-22.
42. Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol 2009;54:160-5.
43. Burch M. Is heart transplantation for adult congenital heart disease an appropriate use of a scarce resource? Heart 2010;96:1172-3.
44. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8.
45. Ganesh JS, Roger CA, Banner NR, et al. Development and validation of a model to predict perioperative mortality following heart transplantation in the UK. J Heart Lung Transplant 2004;23(2 Suppl):S118-19.
46. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28:980-8.
47. Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 2007;167:1998-2005. (Pubitemid 47606641)
48. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170-7.
49. Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 1997;114:627-34. (Pubitemid 27441195)
50. Kalra PR, Bolger AP, Francis DP, et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888-91. (Pubitemid 36363742)
51. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232-7.
52. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
53. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3.
54. Clark AL, Knosalla C, Birks E, et al. Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. Eur J Heart Fail 2007;9:839-44. (Pubitemid 47225164)
55. Bravata DM, Ho SY, Brass LM, et al. Long-term mortality in cerebrovascular disease. Stroke 2003;34:699-704. (Pubitemid 36307396)
56. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
57. Young JN, Yazbeck J, Esposito G, et al. The influence of acute preoperative pulmonary infarction on the results of heart transplantation. J Heart Transplant 1986;5:20-2. (Pubitemid 17039830)
58. Collett D, Mumford L, Banner NR, et al. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010;10:1889-96.
59. Tweezer-Zaks N, Zandman-Goddard G, Lidar M, et al. A long-term follow-up after cardiac transplantation in a lupus patient: case report and review of the literature. Ann N Y Acad Sci 2007;1110:539-43. (Pubitemid 350043043)
60. Moloney ED, Egan JJ, Kelly P, et al. Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant 2005;24:1103-10. (Pubitemid 41127194)
61. Roig E, Almenar L, Gonzalez-Vilchez F, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 2009;9:1414-19.
62. Yager JE, Hernandez AF, Steenbergen C, et al. Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 2005;24:1988-90.
63. Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant 2010;29:432-8.
64. Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transplant 2008;8:866-71. (Pubitemid 351347743)
65. Dobbels F, Vanhaecke J, Dupont L, et al. Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation 2009;87:1497-504.
66. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357:885-96. (Pubitemid 47347322)
67. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 2010;55:1826-34.
68. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
69. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011;123:381-90.
70. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007;133:689-95.
71. Wilson SR, Mudge GH Jr, Stewart GC, et al. Evaluation for a ventricular assist device: selecting the appropriate candidate. Circulation 2009;119:2225-32.
72. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010;29:1-10.
73. Holman WL, Kormos RL, Naftel DC, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant 2009;28:44-50.
74. Goland S, Czer LS, Kass RM, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol 2008;51:1214-20.
75. Venkateswaran RV, Townend JN, Wilson IC, et al. Echocardiography in the potential heart donor. Transplantation 2010;89:894-901.
76. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 2002;106:836-41.